With the estimated revenues of the global biobanking industry reaching US$ 27.54 billion in 2020, backed by an explosive CAGR of 9.5% between now and 2026.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio